In vivo genome-wide CRISPR screens identify SOCS1 as intrinsic checkpoint of CD4 + T H 1 cell response
T cells. Together, these findings identify SOCS1 as a major intracellular negative checkpoint of adoptive T cell response, opening new possibilities to optimize CAR-T cell therapy composition and efficacy.
